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Background: Neuropathic pain is an intractable clinical problem. Intrathecal ketamine, a noncompetitive N–
methyl-D-aspartate receptor (NMDAR) antagonist, is reported to be useful for treating neuropathic pain in clinic by
inhibiting the activity of spinal neurons. Nevertheless, emerging studies have disclosed that spinal astrocytes played
a critical role in the initiation and maintenance of neuropathic pain. However, the present clinical therapeutics is
still just concerning about neuronal participation. Therefore, the present study is to validate the coadministration
effects of a neuronal noncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine and astrocytic
cytotoxin L-a-aminoadipate (LAA) on spinal nerve ligation (SNL)-induced neuropathic pain.
Results: Intrathecal ketamine (10, 100, 1000 μg/kg) or LAA (10, 50, 100 nmol) alleviated SNL-induced mechanical
allodynia in a dose-dependent manner respectively. Phosphorylated NR1 (pNR1) or glial fibrillary acidic protein
(GFAP) expression was down-regulated by intrathecal ketamine (100, 1000 μg/kg) or LAA (50, 100 nmol)
respectively. The combination of ketamine (100 μg/kg) with LAA (50 nmol) showed superadditive effects on
neuropathic pain compared with that of intrathecal administration of either ketamine or LAA alone. Combined
administration obviously relieved mechanical allodynia in a quick and stable manner. Moreover, down-regulation of
pNR1 and GFAP expression were also enhanced by drugs coadministration.
Conclusions: These results suggest that combining NMDAR antagonist ketamine with an astrocytic inhibitor or
cytotoxin, which is suitable for clinical use once synthesized, might be a potential strategy for clinical management
of neuropathic pain.
Background
Neuropathic pain is a formidable clinical problem. Mul-
tiple mechanisms are implicated under neuropathic
pain, such as superexcited primary afferent, abnormal
plasticity in spinal dorsal horn, and aberrant neuron-glia
interactions [1-3].
Abundant laboratory and clinical evidence indicates
that ketamine, a noncompetitive N–methyl-D-aspartate
receptor (NMDAR) antagonist, is useful for treating
neuropathic pain [4,5]. The analgesic effect of ketamine
is trustful, but undesirable side effects exist, such as diz-
ziness, drowsiness, dry mouth, sedation, loss of appetite,
nausea, vomiting and so on [6,7]. The clinical concept
of balanced or associative manner proposes to use a
combination of analgesics or other treatments to pro-
vide better pain relief with minimal side effects [8]. For
instance, studies have indicated that ketamine works
better when combined with morphine, amitriptyline, or
electroacupuncture, respectively [8-10]. All these combi-
nations have well minimized the side effects of keta-
mine, but still fail to provide an ideal analgesic effect on
neuropathic pain. Notably, all of these combinations are
just concern about the neuronal participation in the
neuropathic pain states.
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between neurons and glia is essential for neuropathic
pain processing [1,11,12]. Studies even indicate that glial
activation is required and sufficient for chronic pain
sensitization [13-17]. Therefore, spinal glia should be
considered when treating neuropathic pain. By releasing
neurotransmitters or other extracellular signaling mole-
cules, and reuptaking neurotransmitters among synaptic
cleft, glia can affect neuronal excitability, synaptic trans-
mission and perhaps coordinate activity in neuronal net-
works [1]. The results of previous studies have
implicated spinal cord glial cells (especially astrocytes
and microglia) as key players in the induction and main-
tenance of neuropathic pain [18-20]. Astrocytes are one
of important cells type for maintenance of spinal nerve
ligation (SNL)-induced neuropathic pain [21-23]. There-
fore, inhibition of astrocytic activation could help relieve
neuropathic pain, which breaks the “cross-talk” between
neurons and astrocytes [24].
Taken together, we hypothesized that combination of
NMDAR antagonist ketamine and an astrocytic inhibitor
might exhibit some additive and complementary effects
on neuropathic pain and propose a potential strategy for
therapy.
To test this hypothesis, we employed SNL-induced
neuropathic pain model. ketamine or astrocytes specific
cytotoxin L-a-aminoadipate (LAA) was intrathecally
injected to confirm their individual dose-dependent
analgesia effect. Based on the dose-effect curve, these
two agents were intrathecally coadministrated at the
safe dosages. The analgesic effects of the above men-
tioned treatments were evaluated, while the potential
side effects of ketamine on the motor function were
observed with rotarod test. Western blot and immuno-
histochemistry were performed to confirm the effects of
these two agents, administered individually or together,
on SNL-induced NMDA receptor phosphorylation and
astrocytic activation.
Results
SNL induced significant mechanical allodynia, astrocytic
activation and NMDA receptor phosphorylation
SNL produced rapidly appearing and persistent mechan-
ical allodynia. The paw withdrawal threshold (PWT,
absolute threshold) was much lower in the SNL-Saline
group than that of Sham-Saline or Naïve group on POD
7. The PWTs of Sham-Saline rats were not different
with that of Naïve rats.
Besides, SNL induced a marked astrocytic activation,
indicated by glial fibrillary acidic protein (GFAP) up-reg-
ulation in the ipsilateral spinal dorsal horn of SNL-Sal-
ine group (Fig 1A). Immunohistochemistry of GFAP
indicated that activated astrocytes showed hypertrophied
cell bodies with thickened processes and GFAP-
immunoreactive (IR) staining was enhanced (Fig 1B).
We have observed in our previous study that the SNL-
induced astrocytic activation was not evident on POD 1,
but significant on POD 3, reaching a peak on POD 7,
and remained at high levels at 3 w after SNL [25].
NR1 is the essential subunit of NMDAR [26]. The
functional change of NMDAR induced by SNL was eval-
uated by phosphorylation of NR1 in our experiment.
Compared to that of Sham-Saline group, the level of
anti-phosphorylated NR1 (pNR1) was significantly
Figure 1 Effects of drugs administration on spinal nerve
ligation (SNL) -induced astrocytic activation. A representative
spinal section showed that SNL induced a marked astrocytic
activation in ipsilateral than that of contralateral spinal dorsal horn
(A). B and C show the magnified images of the ipsilateral and
contralateral spinal dorsal horn of SNL rats respectively. Compared
with Sham-Saline rats (D), SNL induced a marked astrocytic
activation (F, J). Intrathecal ketamine (100 μg/kg) didn’t affect
influence astrocytic activation obviously at both 1 d and 3 d after
application (G, K). However, intrathecal LAA (50 nmol) attenuated
SNL-induced astrocytic activation at 1 d after administration
compared with that of SNL-Saline group (H). Astrocytic activation
was further suppressed by coadministration (100 μg/kg of ketamine
and 50 nmol of LAA) than that of LAA (50 nmol) injected alone (I).
Astrocytic activation was returned obvious 3 d after LAA injection
(L). However, drugs coadministration significantly inhibited astrocytic
activation compared to that of LAA alone (M). E, Scheme presenting
an overview over the detected region. N, Statistics of above results.
Scalebar = 800 μmi nA ,2 0μm in B-C and 200 μm in D, F-M. * or #
indicates statistically significant difference with P < 0.05 between
groups. KTM: ketamine, LAA: L-a-aminoadipate.
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compared to Sham-Saline) (Fig 2).
Nociceptive behavioral results could be easily influ-
enced as a result of motor dysfunctions. In order to
assess whether higher dosages of ketamine (100 and
1000 μg/kg) or LAA (50 and 100 nmol) or coadminis-
tration (100 μg/kg ketamine and 50 nmol LAA) could
produce impairment of motor functions, 36 otherwise
experiment-free rats were assessed with the rotarod test.
Neither intrathecal ketamine (100 μg/kg) nor LAA (50
nmol or 100 nmol) affected the motor performance of
rats compared with the control performance at any time
points after injection (Fig 3). Furthermore, coadministra-
tion (100 μg/kg ketamine and 50 nmol LAA) didn’t
influence the motor function either. However, intrathe-
cal ketamine (1000 μg/kg) caused apparent motor dys-
function at 10 min but not other time points after
administration.
These results demonstrated that the anti-allodynia
effects of ketamine (100 μg/kg), LAA (50 nmol or 100
nmol) or coadministration (100 μg/kg ketamine and 50
nmol LAA) did not impair motor function. Intrathecal
ketamine (1000 μg/kg) also exerted effective analgesic
effect except the motor impairment at the first 10 min
after administration (Fig 3). Therefore, the PWT at
10 min after ketamine (1000 μg/kg) administration was
omitted.
Ketamine or LAA attenuated SNL-induced mechanical
allodynia individually in dose-dependent manners
In order to confirm the effects of intrathecal ketamine
or LAA on SNL-induced neuropathic pain, we injected
these two agents individually with three different con-
centrations and observed the changes of PWT at differ-
ent time points after injection on POD 7.
Intrathecally administering 10 μg/kg of ketamine
could elevate PWT slightly at 10 min after administra-
tion, but there were no statistical differences compared
to that of SNL-Saline group at any time points (Fig 4A,
P > 0.05). Intrathecal ketamine (100 μg/kg) elevated
PWT significantly 10 min post injection and this anti-
allodynia effect lasted to 12 h after administration.
Besides, a higher dose of ketamine (1000 μg/kg) elevated
PWT apparently 30 min after injection compared to
that of saline control and this effect persisted for about
24 h (Fig 4A, P < 0.05). We also observed that the anti-
allodynia effect of 1000 μg/kg ketamine was better than
that of 100 μg/kg ketamine (Fig 4A, P < 0.05). All of
these results demonstrated that intrathecal ketamine
Figure 2 Effects of drugs administration on SNL-induced NR1
phosphorylation. Phosphorylated NR1 (pNR1) level was much
higher in SNL-Saline group than that of Sham-Saline group (* P <
0.05). Intrathecal ketamine (100 μg/kg) down-regulated pNR1 level
compared with that of SNL-Saline group. Coadministration further
inhibited pNR1 expression than that of individual ketamine injection.
Furthermore, pNR1 returned to high level at 1 d after individual
ketamine injection. However, pNR1 remained low at 1 d in the
coadministration group compared with that of individual ketamine
injection. Additionally, LAA application alone has no obvious effects
on SNL-induced NR1 phosphorylation. *, # and $ each indicates
statistically significant difference with P < 0.05 between groups.
Figure 3 Effects of ketamine and/or LAA on rats’ motor
performance in rotarod test. Immediately after a baseline
response was obtained, saline or drugs were administered
intrathecally to normal rats and rotarod test was performed at
different time points thereafter (6 rats in each group). The score of
each group was normalized as a percentage of the baseline value.
Compared with baseline, there was no statistical difference obtained
from rotarod test after drugs injection, but intrathecally
administered 1000 μg/kg of ketamine caused an obvious defect on
rotarod test at 10 min after injection. * P < 0.05 compared with
baseline response.
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anti-allodynia effect in a dose-dependent manner on
SNL-induced neuropathic pain, which was a very quick
but short effect (Fig 4A).
Intrathecal 10 nmol of LAA could only suppress SNL-
induced mechanical allodynia at 24 h after administra-
tion (Fig 4B, P < 0.05). However, a higher dose of LAA
(50 nmol) did elevate PWT at 1 h, with the peak effect
occurring at 12 h, and lasted to 48 h after injection,
which showed statistical difference with that of SNL-
Saline group (Fig 4B, P < 0.05). Furthermore, 100 nmol
of LAA increased PWT in a more persistent and stron-
ger way compared to that of saline control with its
analgesic effects emerged at 30 min, reaching the peak
at 12 h, and lasted to 72 h after administration.
Intrathecal 100 nmol of LAA produced more significant
anti-allodynia effects than that of 50 nmol of LAA (at
30 min, 12 h after administration and thereafter; Fig 4B,
P < 0.05). These results indicated the dose-related anti-
allodynia effect of intrathecal LAA (10, 50 or 100 nmol)
on SNL-induced neuropathic pain, which was a late but
persistent effect (Fig 4B).
The above results showed that the anti-allodynia effect
of ketamine or LAA was significant, dose-related but
exhibited individually different effecting patterns: quick
but short for ketamine, late but persistent for LAA.
Effects of combining ketamine with LAA on SNL-induced
neuropathic pain
To investigate whether combining NMDAR antagonist
ketamine with astrocytic inhibitor LAA could exert
some additive and complementary effects on SNL-
induced neuropathic pain, we coadministrated ketamine
(100 μg/kg) and LAA (50 nmol) simultaneously to SNL
rats on POD 7 intrathecally. Then we compared the
effect of coadministration (ketamine 100 μg/kg and LAA
50 nmol) with that of individual administration (keta-
mine 100 μg/kg or LAA 50 nmol).
The anti-allodynia effect of coadministration appeared
at 10 min, reaching the peak at 2 h, and lasted to 72 h
after injection. Besides, PWTs of coadministration group
were much higher than that of individual ketamine (100
μg/kg) or LAA (50 nmol) injection at any time points
after administration (Fig 5A, P < 0.05). These results
implied that the anti-allodynia effect of coadministration
was a very quick, stable and long lasting response
(Fig 5A’).
Furthermore, we compared the analgesic effects of
coadministration (ketamine 100 μg/kg and LAA
50 nmol) with that of intrathecal ketamine (1000 μg/kg)
or LAA (100 nmol), respectively. Ketamine (1000 μg/kg)
showed stronger analgesic effect only at 30 min after
administration than that of coadministration group
(Fig 5B, P < 0.05). However, there was no statistical
difference between coadministration and ketamine
1000 μg/kg at 1 h after administration. Moreover, at 2 h
after injection, coadministration showed stronger analge-
sic effects than that of single ketamine (1000 μg/kg) on
PWTs (Fig 5B, P < 0.05). Furthermore, coadministration
produced stronger effect on PWTs compared with that
of LAA (100 nmol) in the first 6 h after administration.
However, there were no statistical differences between
coadministration and single LAA (100 nmol) at 12 h
after administration and thereafter (Fig 5B).
These results suggested that the anti-allodynia effect
of coadministration (ketamine 100 μg/kg and LAA 50
nmol) produced a more persistent and effective role
than that of individual administration either at mild or
high dosage (Fig 5B’). Therefore, we concluded that
combining ketamine (100 μg/kg) with LAA (50 nmol)
showed some additive and complementary effects on
SNL-induced neuropathic pain.
Figure 4 Effects of intrathecal ketamine or LAA on SNL-induced mechanical allodynia, respectively. Intrathecal ketamine elevated paw
withdrawal thresholds (PWTs) in a dose-dependent manner (A). *, # P < 0.05 compared with that of Saline or 100 μg/kg of ketamine,
respectively. Intrathecal LAA attenuated SNL-induced mechanical allodynia individually in a dose-dependent manner (B). *, # P < 0.05 compared
with that of Saline or 50 nmol of LAA, respectively.
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phosphorylation
In order to disclose the underlying mechanisms about the
additive and complementary effect of coadministration,
Western blot with antibody against pNR1 was performed
to detect the NMDAR phosphorylation. The results of
behavioral study showed that ketamine exerted strong
effect from 30 min to 2 h after given and this effect disap-
peared at 24 h after administration. Therefore, we chose
2 h and 24 h to check the expression of pNR1.
The results showed that ketamine (100 μg/kg) alone
significantly down-regulated pNR1 expression at 2 h
after administration compared with that of SNL-Saline
group (Fig 2, P < 0.05). However, no significant differ-
ence could be observed between LAA alone and saline
control groups. Drugs coadministration (ketamine 100
μg/kg and LAA 50 nmol) inhibited pNR1 at 2 h after
injection, which was obviously lower than that of indivi-
dual ketamine injection (100 μg/kg) (Fig 2, P <0 . 0 5 ) .
The NR1 phosphorylation returned to high level at 24 h
after ketamine (100 μg/kg) injected alone (P > 0.05 com-
pared to SNL-Saline group). However, the level of pNR1
remained low at 24 h after drugs coadministration com-
pared with that of individual ketamine injection or SNL-
Saline group (Fig 2, P < 0.05).
These results indicated that the anti-allodynia effect of
ketamine on neuropathic pain was mainly via suppres-
sion of NMDAR function. Moreover, astrocytic inhibitor
LAA could enhance the inhibitory effect of ketamine on
NMDAR functioning.
Figure 5 Effects of combining ketamine with LAA on SNL-induced mechanical allodynia. PWTs of coadministration group were much
higher than that of individual ketamine (100 μg/kg) or LAA (50 nmol) injection at any time points after administration (A). #, $ P < 0.05
compared with that of ketamine 100 μg/kg or LAA 50 nmol, respectively. A’, Schematic curves according to A implied that compared with that
of individual administration, the anti-allodynia effect of coadministration was more quick, stable and persistent. The analgesic effects of
coadministration (100 μg/kg of ketamine and 50 nmol of LAA) compared with that of higher doses of individual ketamine (1000 μg/kg) or LAA
(100 nmol), respectively (B). * P < 0.05 compared with that of Ketamine-LAA group. #, $ P < 0.05 compared with that of 1000 μg/kg of ketamine
or 100 nmol of LAA, respectively. B’, Schematic curves according to B implied that even compared with that of higher doses of individual
administration, the anti-allodynia effect of coadministration was still more stable and long-lasting.
Mei et al. Molecular Pain 2010, 6:50
http://www.molecularpain.com/content/6/1/50
Page 5 of 11Effects of LAA on SNL-induced astrocytic activation
Immunohistochemistry with antibody against astrocytic
specific marker GFAP was performed to detect the
astrocytic activation. Behavioral results showed that the
effect of intrathecal LAA peaked at 1 d after given and
could not persist more than 3 d. So, we chose the time
point of 1 d and 3 d to detect GFAP expression.
The results showed that LAA (50 nmol) alone attenu-
ated SNL-induced astrocytic activation at 24 h after
administration (Fig 1H), where intrathecal ketamine
(100 μg/kg) didn’t change SNL-induced microglia activa-
tion 1 d after administration (Fig 1G). Furthermore,
GFAP expression was obviously down-regulated 24 h
after coadministration (ketamine 100 μg/kg and LAA
50 nmol), which was much lower than that of LAA
(50 nmol) or ketamine (100 μg / k g )i n j e c t e da l o n e
(Fig 1I). GFAP expression returned to high level at 72 h
after LAA (50 nmol) injection (Fig 1L). Meanwhile,
intrathecal ketamine (100 μg/kg) didn’ts h o wa n y
obvious effects on SNL-induced microglia activation 3 d
after application (Fig 1K). However, astrocytic activation
was significantly inhibited by drugs coadministration
compared to that of intrathecal LAA (50 nmol) or keta-
mine (100 μg/kg) alone (Fig 1M).
These results suggested that NMDAR antagonist keta-
mine could facilitate the inhibitory effect of LAA on
astrocytic activation.
Discussion
In the present study, we showed that: 1. SNL induced
persistent mechanical allodynia with NMDAR phosphor-
ylation and astrocytic activation in spinal dorsal horn. 2.
Intrathecal application of NMDAR antagonist ketamine
alleviated mechanical allodynia with decreased NMDAR
phosphorylation in a quick but short response, whereas
astrocytic cytotoxin LAA relieved mechanical allodynia
with attenuated astrocytic activation in a late but persis-
tent manner. 3. Combining ketamine with LAA sup-
pressed neuropathic pain in a quick and stable way,
whereas, NMDAR phosphorylation and astrocytic activa-
tion were both much more suppressed than those of
either single drug administration. Taken together, com-
bination of NMDAR antagonist and astrocytic inhibitor
exhibited some additive and complementary analgesic
effects on SNL-induced neuropathic pain.
Effects of ketamine on neuropathic pain
Clinical study shows that intrathecal ketamine is useful
for treating neuropathic pain [27] at a sub-anesthetic
dosage due to the sedation and other side effects when it
is applied at high dose [7]. In the present study, intrathe-
cal ketamine attenuates SNL-induced mechanical allody-
nia in a dose dependant manner. Spinal NMDAR plays
an important role in the development of central
sensitization and neuropathic pain via the induction of
long-term potentiation (LTP) in dorsal horn nociceptive
synaptic transmission. As a functional subunit of
NMDAR, NR1 phosphorylation is significantly increased
in the ipsilateral spinal cord after nerve injury and coin-
cides with mechanical allodynia [28]. Previous study sug-
gests that ketamine combined with methamphetamine
could down-regulate NR1 receptor phosphorylation in
rats (phosphorylation site: serine 897) [29]. Moreover, it
is reported that NR1 subunit knockout mice are more
resistant to ketamine than control wide type mice, indi-
cating that NMDAR NR1 subunit contributes to media-
tion of ketamine anesthesia or analgesia [30]. The
detailed mechanisms underlying ketamine-induced
dephosphorylation of NR1 are still unclear. Ketamine
could block Ca
2+ influx through the NMDA receptor,
and then the lowered intracellular Ca
2+ decreases the
activity of protein kinase C (PKC) and some other intra-
cellular signals [31,32].Inhibition of PKC activity could
block capsicin-induced phosphorylation of NR1 [33].
Additionally, PKA activation mediates NR1 phosphoryla-
tion in SNL-induced neuropathic pain [28]. Therefore, it
is possible that ketamine blocks NMDA receptor and
inhibits intracellular PKA, PKC or signals activity, and
then decreases NR1 phosphorylation.
In the present study, intrathecal ketamine alleviated
mechanical allodynia mainly via suppressing the func-
tion of NR1. Therefore, blocking NMDA receptor may
be the primary anti-allodynic mechanism of ketamine
observed in the present study.
Effects of the astrocytic specific inhibitor on neuropathic
pain
Spinal microglia and astrocytes are both important for
the development of neuropathic pain. In SNL-induced
neuropathic pain, studies showed that activation of ERK
and p38 only presented in spinal microglia at the initia-
tion of neuropathic pain [23,34]. Zhuang et al [23] also
observed that there was a sequential activation of neu-
rons, microglia and astrocytes following SNL. These
results support a role for microglia in the early establish-
ment of SNL-induced neuropathic pain and predict the
role for astrocytes in the maintenance of neuropathic
pain. Therefore, astrocytes are one of the important cell
types for maintenance of SNL-induced neuropathic pain,
which is very important for the chronic process of neuro-
pathic pain. Cumulating evidence has shown a critical
role for activated astrocytes in nerve injury-induced neu-
ropathic pain [35]. Ultrastructural evidence suggests that
cell degeneration and death are confined to astrocytes
after the injection of LAA into the striatum [36]. Consis-
tent with a previous study [21], we demonstrated that
LAA relieved late phase mechanical allodynia in a dose
dependent manner. In the present experiment, we
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allodynia was suppressed and GFAP expression was
down regulated. These results indicated that inhibition of
astrocytic activation may be a useful way to conquer neu-
ropathic pain, which may be a complementary option to
modern neuronal based therapeutics.
Drugs combination
The clinical concept of balanced or associative manner
proposes to use a combination of analgesics and other
treatments to provide better pain relief and minimized
side effects [8-10]. However, all of them only concerned
about the neuronal participation in the neuropathic pain
states. Spinal astrocytes play important roles in the devel-
opment of SNL-induced neuropathic pain. Therefore,
combining ketamine with the astrocytic inhibitor may
provide a potential strategy for treating neuropathic pain.
In the present study, we observed that combination of
ketamine and LAA showed additive and complementary
effects of anti-allodynia. The analgesic effect of coadmi-
nistration appeared earlier than that of intrathecal
ketamine alone. Moreover, the peak effect of coadminis-
tration was much stronger than that of individual keta-
mine or LAA injection. Furthermore, the combination
of drug administration exerted more powerful inhibition
on NR1 phosphorylation and astrocytic activation. Our
results suggest that combination of NMDAR antagonist
ketamine and astrocytic cytotoxin LAA is an effective
way to relieve SNL-induced mechanical allodynia. Then
we further search for the underlying mechanisms of this
effect.
Intrathecal ketamine enhanced the analgesic effect of
LAA on tactile allodynia and potentiated the inhibitory
effect of LAA on astrocytic activation. As observed in
our previous study, inhibiting astrocytic activation is
probably a novel analgesic mechanism of ketamine [37].
Some opioid receptors (μ,  and δ subtypes) and toll
like receptors (TLRs) are expressed on astrocytes. It is
shown that ketamine can function on opioid receptors
[38,39] and TLRs [40-42] and thus inhibiting astrocytic
activation. Besides, nitric oxide (NO) released following
NMDAR activation could induce astrocytic activation
[43]. Consequently, blocking NMDAR-NO pathway
probably prevents astrocytic activation. All of these evi-
dence supported our results that intrathecal ketamine
facilitated the effects of astrocytic inhibitor LAA both
on anti-allodynia and GFAP down-regulation.
On the other hand, our study observed that astrocytic
toxin LAA could facilitate the effects of ketamine on
neuropathic pain relief and reduction of pNR1 level.
Studies indicated that some “gliotransmitters”,p r o i n -
flammatory cytokine and chemokine released from acti-
vated astrocytes could facilitate neuronal activity
[20,44-46]. Therefore, blocking astrocytic activation
might dephosphorylate NR1. Recent studies show that
glutamate exocytose from astrocytes enhanced synaptic
strength at excitatory synapses [45,47]. This effect is
mainly mediated by neuronal NMDAR. Therefore, inhi-
biting astrocytic activation (e.g. with LAA in our study)
could down-regulate activation of NMDAR via prevent-
ing glutamate release from astrocytes. In addition,
emerging literature implicates a role for glia-cytokines-
neurons in persistent pain [12]. Nerve injury induces
astrocytic activation and release of some proinflamma-
tory cytokines. It is confirmed that pain-induced up-
regulation of IL-1b is selectively localized to astrocytes,
while IL-1 receptor (IL-1R) is exclusively expressed on
neurons [12,48]. Furthermore, it is showed that IL-1R
and NR1 are co-localized in spinal neurons [48]. Apply-
ing IL-1R antagonist and glial inhibitor, attenuates
NMDAR phosphorylation [48]. In vitro application of
IL-1b induces NR1 phosphorylation, which is blocked
by an IL-1R antagonist [12]. These results further pro-
vide evidence for our study that LAA could decrease
pNR1, and thus enhances the role of ketamine.
LAA is a kind of toxin and cannot be used as a clini-
cal drug although it can produce significant analgesic
effects. However, in the present study, LAA is used to
confirm the active participation of astrocytes in neuro-
pathic pain. More importantly, we want to provide a
potential strategy on the treatment of neuropathic pain.
It is expected that in the future, some analgesic treat-
ments targeting astrocytes with limited side effects will
be developed.
In conclusion, the results of the present study show that
ketamine and LAA individually present anti-allodynic
effects in neuropathic pain, whereas their coadministration
exhibits additive and complementary effects on mechani-
cal allodynia. This combination of these two drugs pro-
vided a quick, stable and enhanced effect, with less side
effects of ketamine in current treatment. Although LAA is
now just used in experimental study but not clinical
research or therapy, our results provide a new potential
strategy for treating clinical neuropathic pain.
Methods
Animals preparation
Male Sprague-Dawley rats (180-200 g) were housed in
plastic cages, and maintained on a 12:12 h light/dark
cycle under conditions of 22-25°C ambient temperature
with food and water available. Totally 160 rats contribu-
ted to the whole experiments. All experimental proce-
dures received prior approval from the Animal Use and
Care Committee for Research and Education of the
Fourth Military Medical University (Xi’an, China), and
the ethical guidelines to investigate experimental pain in
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mize animal suffering and to reduce the number of
animals used.
Intrathecal implantation
Intrathecal implantation was performed by inserting
polyethylene (PE) tubing to inject the drug directly into
the subarachnoid space of the lumbar enlargement.
Briefly, a midline incision (3 cm) was made at the back
of the rat at the level of the thoracic vertebrae, under
pentobarbital anesthesia (45 mg/kg, i.p.). A pre-mea-
sured length of PE-10 tubing (I.D. 0.28 mm and O.D.
0.61 mm) was passed caudally from the T8 to the L3
level of the spinal cord, and 2 cm of the free ending was
left exposed in the upper thoracic region. Rats were
allowed to recover for a 3-5 d before further use. Only
the animals judged as neurologically normal and that
showed complete paralysis of the tail and bilateral hind
legs after administration of 2% lidocaine (10 μl) through
the intrathecal catheter were used for the following
experiments.
SNL
To create the rat SNL model, under pentobarbital
anesthesia (45 mg/kg, i.p.), the left transverse process of
the L5 vertebra was first removed to expose the L4 and
L5 spinal nerves. The L5 spinal nerve was then carefully
isolated and tightly ligated with 6-0 silk thread [50]. The
surgical procedure for the sham group was identical to
that of the SNL group, except that the spinal nerve was
not ligated. Animals were raised for 1 w till the intrathe-
cal drugs administration on post operative day (POD) 7.
Intrathecal drugs administration
The astrocytic cytotoxin LAA (Sigma, St. Louis, MO,
USA) and S(+)-ketamine hydrochloride (Sigma) were
dissolved and diluted with preservative-free normal
saline solution for administration. Normal saline (0.9%)
was used as the negative control. Animals were divided
into 5 groups for administration: Sham-Saline group (n
=6 ,av o l u m eo f1 0μl normal saline was injected into
sham rats), SNL-Saline group (n = 6, a volume of 10 μl
normal saline was injected into SNL rats), SNL-Keta-
mine group (n = 6 for each 3 subgroups; 10 μl of 10,
100 or 1000 μg/kg ketamine was injected into SNL rats,
respectively), SNL-LAA group (n = 6 for each 3 sub-
groups; 10 μl of 10, 50 or 100 nmol LAA was injected
into SNL rats, respectively), SNL-Ketamine-LAA group
(n = 6; 50 nmol LAA together with 100 μg/kg ketamine
in a total volume of 10 μl was injected into SNL rats,
respectively). Drugs and saline were injected intrathe-
cally over 30 s, followed by a 10 μlf l u s ho fn o r m a l
saline.
Nociceptive behavioral tests
Animals were habituated to the testing environment for
3 d before baseline testing, and then were placed under
inverted plastic boxes (30 × 30 × 50 cm
3)o na ne l e v a t e d
mesh floor and allowed to habituate for 30 min before the
threshold testing. Briefly, a logarithmic series of 8 cali-
brated Semmes-Weinstein monofilaments (von-Frey hairs;
Stoelting, Kiel, WI, USA) were applied to the ipsilateral
hindpaws to determine the stimulus intensity threshold
stiffness required to elicit a paw withdrawal response. Log
stiffness of the hairs is determined by log10 (milligrams ×
10) [17]. The 8 filaments had the following log-stiffness
values (value in grams is given in parentheses): 4.17 (1479
mg), 4.31 (2041 mg), 4.56 (3630 mg), 4.74 (5495 mg), 4.93
(8511 mg), 5.07 (11749 mg), 5.18 (15136 mg), and 5.46
(28840 mg). The range of monofilaments (1.479-28.840
gm) produced a logarithmically graded slope when inter-
polating a 50% response threshold of stimulus intensity
(expressed as log10 (milligrams × 10)) [51]. Assessments
were made before surgery for baseline value. Then on
POD 7, behavioral tests were performed 30 min before,
a n d1 0m i n ,3 0m i n ,6 0m i n ,2h ,6h ,1 2h ,2 4h ,4 8h ,a n d
72 h after drug administration, respectively. The beha-
vioral responses were used to calculate the 50% PWT, by
fitting a Gaussian integral psychometric function using a
maximum-likelihood fitting method, as described in detail
previously [17]. This fitting method allowed parametric
statistical analysis. All the PWT tests were performed in a
double-blind manner.
Rotarod test
In order to assess whether the drugs used in the present
experiment could influence motor function, which
might influence the behavioral results, we performed
rotarod tests on drug administered but operation- and
behavioral observation-free rats. Rats with no previous
exposures to the rotarod test were placed on the Ugo
Basile 7650 Rotarod accelerator treadmill (Ugo Basile,
Varese, Italy) set at the minimal speed for training ses-
sions of 1-2 min at intervals of 30-60 min. After this
learning period, the animals were placed on to the
rotarod at a constant speed of 25 RPM. As the animal
took a grip of the drum, the accelerator mode was
selected on the treadmill, i.e. the rotation rate of the
drum was increased linearly at 20 RPM. Thereafter, the
time was measured from the start of the acceleration
period until the rat fell off the drum. The cut-off time
was 30 s. Each rat was tested 30 min before as control
performance and at 10 min, 30 min, 60 min, 2 h, 6 h,
12 h, 24 h, 48 h, and 72 h after drugs administration,
respectively. The time that the animal remained on the
rotarod was recorded and expressed as a percentage of
that animal’s own mean control performance.
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After deeply anesthesia with pentobarbital (60 mg/kg,
i.p.), the rats were perfused through the ascending aorta
with 100 ml 0.9% saline followed by 500 ml 0.1 M phos-
phate buffer (PB, pH 7.3) that contained 4% paraformal-
dehyde and 2% picric acid. After perfusion, the L5
spinal segment was removed and post-fixed in the same
fixative for 2-4 h and then cryoprotected for 24 h at 4°C
in 0.1 M PB that contained 30% sucrose. Transverse fro-
zen spinal sections (30 μm thick) were cut with a cryo-
stat (Leica CM1800; Heidelberg, Germany) and collected
serially in three dishes. Each dish contained a complete
set of serial sections that were processed for immuno-
fluorescent staining. One of the dishes was selected ran-
domly. The sections in the dish were rinsed in 0.01 M
phosphate-buffered saline (PBS, pH 7.3) three times
(10 min each), blocked with 2% goat serum in 0.01 M
PBS that contained 0.3% Triton X-100 for 1 h at room
temperature (RT, 20-25°C), and then used for immuno-
fluorescent staining. The sections were incubated over-
n i g h ta t4 ° Cw i t hp r i m a r ya ntibody: mouse anti-GFAP
(1:5000; Chemicon, Temecula, CA, USA). The sections
were washed three times in 0.01 M PBS (10 min each)
and then incubated for 4 h at RT with the secondary
antibody: FITC-conjugated horse anti-mouse IgG (1:500;
Vector, Burlingame, CA, USA). The specificity of the
staining was tested on the sections in another dish by
omission of the primary specific antibodies. No immu-
noreactive products were found on the sections (data
not shown). Confocal images were obtained using a con-
focal laser microscope (FV1000; Olympus, Tokyo, Japan)
and digital images were captured with Fluoview 1000
(Olympus). For semi-quantification, the fluorescent
brightness value of GFAP-like immunoreactivity was
detected on the same areas of the dorsal horn by using
software under IX-70 confocal microscope. After the
images were captured, optical density (OD) of the same
areas of the ipsilateral superficial dorsal horn (laminae I
and II, Fig 1K) was calculated and averaged across the
five spinal sections [25]. The relative value of GFAP
immunodensity was expressed as percentage changes
compared to the Sham-Saline control.
Western blot
Animals were rapidly sacrificed and the L5 dorsal horns
were rapidly removed and frozen on dry ice for western
blot. The spinal dorsal horn was dissected using the
“open book” method [23]. Briefly, the L5 spinal cord
segment was dissected according to the termination of
the L4 and L5 dorsal roots. Then, the spinal segment
w a sc u ti n t oal e f ta n dr i g h th a l ff r o mt h em i d l i n e .
Finally, the left half was further split into the dorsal and
ventral horns at the level of the central canal. The
selected region was homogenized with a hand-held pes-
tle in SDS sample buffer (10 ml mg
-1 tissue), which con-
tained a cocktail of proteinase and phosphatase
inhibitors. The electrophoresis samples were heated at
100°C for 5 min and loaded onto 10% SDS-polyacryla-
mide gels with standard Laemmli solutions (Bio-Rad
Laboratories, CA, USA). The proteins were electro-
blotted onto a polyvinylidene difluoride membrane
(PVDF, Immobilon-P, Millipore, Billerica, MA, USA).
The membranes were placed in a blocking solution,
which contained Tris-buffered saline with 0.02% Tween
(TBS-T) and 5% non-fat dry milk, for 1 h, and incubated
overnight under gentle agitation with primary antibo-
dies: mouse anti-pNR1 (1: 500; Sigma) and rabbit anti-
b-actin (1: 1000; Sigma). Bound primary antibodies were
detected with the anti-rabbit or anti-mouse horseradish
peroxidase (HRP)-conjugated secondary antibody
(1:10000; Amersham Pharmacia Biotech Inc., Piscataway,
NJ, USA). Between each step, the immunoblots were
rinsed with TBS-T. All reactions were detected by the
enhanced chemiluminescence (ECL) detection method
(Amersham). The densities of protein blots were
analyzed by using Labworks Software (Ultra-Violet Pro-
ducts, UK). The densities of pNR1 and b-actin immu-
noreactive bands were quantified with background
subtraction. The same size of square was drawn around
each band to measure the density and the background
near that band was subtracted. Since b-actin levels did
not change significantly after inflammation and nerve
injury [12], we used b-actin levels as a loading control,
and pNR1 levels were normalized against b-actin levels
and expressed as percentage changes compared to the
Sham-Saline control.
Quantification and statistical analysis
All data were collected by researchers blinded to the
surgery and reagents used. Data from western blot and
immunohistochemistry were expressed as mean ± SD.
Differences in changes of values over time of each
group were tested using one-way ANOVA, followed by
t h el e a s ts i g n i f i c a n td i f f e r e n c et e s t .D a t af r o mt h ev o n -
Frey test were presented as mean ± SD and analyzed as
the interpolated 50% threshold (absolute threshold) in
log base 10 of stimulus intensity (monofilament stiffness
in milligrams × 10). Repeated measures ANOVA (with
Bonferroni confidence interval adjustment) was used
and conducted for analyzing. Data from the rotarod test
were presented as mean ± SD. Repeated measures
ANOVA (with Bonferroni confidence interval adjust-
ment) was used and conducted for analyzing. All statis-
tical analyses were performed using SPSS® version 16.0
software (SPSS Inc., Chicago, IL, USA). P <0 . 0 5w a s
considered statistically significant.
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